The effects of vitamin D3 supplementation on some metabolic and inflammatory markers in diabetic nephropathy patients with marginal status of vitamin D: A randomized double blind placebo controlled clinical trial.

What Was Tested

This randomized controlled trial looks at Vitamin D, K2, Magnesium and Zinc.

Diabetic nephropathy is known to be an independent risk factor in the progression of renal and cardiovascular disorders.

Due to the association between vitamin D deficiency and diabetic nephropathy, vitamin D deficiency in the diabetic nephropathy population, this study conducted to examine the effects of Vitamin D3 on metabolic and inflammatory parameters in patients with diabetic nephropathy.

Who Took Part

The abstract describes 50 patients taking part.

PubMed indexes the participants as young adults, adults and middle-aged adults, both men and women.

This eight-week, randomized, double-blind, placebo-controlled trial was carried out on 50 diabetic nephropathy patients with marginal status of vitamin D.

Participants were randomly assigned to two groups: control and intervention.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

Because people in this Vitamin D, K2, Magnesium and Zinc study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the patients and researchers unaware of who received Vitamin D, K2, Magnesium and Zinc.

A placebo (an inactive look-alike) gave the Vitamin D, K2, Magnesium and Zinc group a baseline to be compared against.

Fasting blood samples were collected from all patients at their entry to the study, and eight weeks after intervention.

What Was Measured

PubMed files the paper under topics including Biomarkers, Case-Control Studies, Cholecalciferol, Diabetic Nephropathies, Dietary Supplements, Inflammation and Metabolic Diseases.

Author keywords: Diabetes, Nephropathy and Vitamin D.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in 50 patients.

Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2019 (Diabetes & metabolic syndrome), a journal based in Netherlands.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.